Latest market price
11.47
-0.31-2.63%
TA
Loading chart...
Snapshot
| Index | — | P/E | — | EPS (ttm) | -3.85 | Insider Own | 35.15% | Shs Outstand | 85.11M | Perf Week | -2.88% |
| Market Cap | 976.17M | Forward P/E | — | EPS next Y | -3.41 | Insider Trans | -1.62% | Shs Float | 75.12M | Perf Month | 0.53% |
| Enterprise Value | 540.17M | PEG | — | EPS next Q | -0.77 | Short Float | 10.43% | Perf Quarter | -36.03% | ||
| Income | -264.00M | P/S | — | EPS this Y | — | Short Ratio | 5.19 | Perf Half Y | -34.68% | ||
| Sales | 0.00 | P/B | 2.28 | EPS next Y | — | ROA | -45.94% | Short Interest | 7.83M | Perf YTD | -12.97% |
| Book/sh | 5.03 | P/C | 1.82 | EPS next 5Y | — | ROE | -82.68% | 52W High | 23.29 -50.75% | Perf Year | 16.92% |
| Cash/sh | 6.31 | P/FCF | — | EPS past 3/5Y | — | ROIC | -50.65% | 52W Low | 9.46 21.25% | Perf 3Y | -77.75% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | — | Gross Margin | 0.00% | Volatility | 5.98% 6.60% | Perf 5Y | 15.86% |
| Dividend TTM | — | EV/Sales | — | EPS Y/Y TTM | — | Oper. Margin | 0.00% | ATR (14) | 0.75 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 12.56 | Sales Y/Y TTM | — | Profit Margin | 0.00% | RSI (14) | 47.69 | Recom | 2.32 |
| Dividend Gr. 3/5Y | — | Current Ratio | 12.56 | EPS Q/Q | 3.45% | SMA20 | 3.83% | Beta | 1.12 | Target Price | — |
| Payout | 0.00% | Debt/Eq | 0.24 | Sales Q/Q | — | SMA50 | -7.77% | Rel Volume | 0.56 | Prev Close | 11.78 |
| Employees | 130 | LT Debt/Eq | 0.24 | Earnings | Nov 04 | SMA200 | -30.23% | Avg Volume | 1.70M | Price | 11.47 |
| IPO Date | Oct 20, 2020 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 8.48% — | Net Debt/EBITDA | — | Volume | 946,899 | Change | -2.63% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-13-26 | Reiterated | HC Wainwright & Co. | Buy | $45 |
| May-11-26 | Reiterated | HC Wainwright & Co. | Buy | $32 → $45 |
| Mar-23-26 | Upgrade | Wolfe Research | Underperform → Outperform | |
| Mar-19-26 | Upgrade | Rothschild & Co | Neutral → Buy | |
| Feb-24-26 | Reiterated | Oppenheimer | Outperform | $30 → $35 |
| Jan-15-26 | Downgrade | Goldman Sachs | Neutral → Sell | $10 |
| Jan-09-26 | Reiterated | UBS | $45 → $24 | |
| Jan-09-26 | Reiterated | HC Wainwright & Co. | Buy | $26 → $32 |
| Jan-09-26 | Upgrade | BTIG | Neutral → Buy | |
| Jan-08-26 | Reiterated | UBS | $12 → $45 |
Latest News· Times ET
Oct-25-26
Oct-25-2606:15AM
Oct-22-26
Oct-20-26
Oct-05-26
Oct-05-2611:26AM
Sep-30-26
Sep-30-2612:19PM
Sep-21-26
Sep-21-2601:00PM
Sep-11-26
Sep-11-2601:48PM
Sep-08-26
Sep-08-2610:35AM
Aug-13-26
Aug-11-26
Aug-11-2601:21AM
Aug-10-26
08:07AM
Aug-06-26
Aug-06-2603:13AM
Jul-31-26
Company
MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 | — | — | — | |
| Cost of Goods Sold Incl. D&A | 2 | 3 | 0 | 0 | — | — | — | |
| Gross Profit | -2 | -3 | 0 | 0 | — | — | — | |
| Selling, General and Administrative Excl. Other | 47 | 42 | 30 | 22 | — | — | — | |
| Research and Development | 222 | 203 | 113 | 32 | — | — | — | |
| Other Operating Expense | -3 | -3 | 0 | 0 | — | — | — | |
| Operating Income | -268 | -245 | -143 | -54 | — | — | — | |
| Interest Expense | 10 | 7 | 0 | 0 | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 14 | 22 | 22 | 10 | — | — | — | |
| Net Income Before Taxes | -265 | -230 | -121 | -44 | — | — | — | |
| Income Taxes | 1 | 1 | 0 | 0 | — | — | — | |
| Consolidated Net Income | -264 | -227 | -119 | -36 | — | — | — | |
| Net Income From Continuing Operations | -266 | -230 | -121 | -44 | — | — | — | |
| Net Income | -264 | -227 | -119 | -36 | — | — | — | |
| EPS (Recurring) | -3.85 | -3.53 | -1.89 | -0.73 | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -3.85 | -3.53 | -1.89 | -0.73 | — | — | — | |
| EPS (Diluted) | -3.85 | -3.53 | -1.89 | -0.73 | — | — | — | |
| EBITDA | -251 | -220 | -120 | -44 | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | |
| Shares Outstanding | 74 | 64 | 63 | 49 | — | — | — | |
| Market Capitalization | 849 | 844 | 3,411 | 2,959 | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Reich Kristian | Chief Scientific Officer | Jul 27 '26 | Sale | 20.00 | 1,100 | 22,000 | 2,711,198 | Jul 29 |
| Reich Kristian | Chief Scientific Officer | Jul 22 '26 | Sale | 20.00 | 2,448 | 48,960 | 2,712,298 | Jul 23 |
| Reich Kristian | Chief Scientific Officer | Jul 21 '26 | Sale | 20.02 | 50,000 | 1,001,000 | 2,714,746 | Jul 23 |
| Reich Kristian | Chief Scientific Officer | Jul 20 '26 | Sale | 20.09 | 43,700 | 877,933 | 2,764,746 | Jul 21 |
| Reich Kristian | Chief Scientific Officer | Jul 15 '26 | Sale | 20.01 | 16,105 | 322,261 | 2,808,446 | Jul 20 |
| Santos da Silva Jorge | Chief Executive Officer | Jul 10 '26 | Sale | 20.02 | 68,289 | 1,367,146 | 2,774,893 | Jul 13 |
| Santos da Silva Jorge | Chief Executive Officer | Jul 09 '26 | Sale | 20.01 | 33,936 | 679,059 | 2,843,182 | Jul 13 |
| Santos da Silva Jorge | Chief Executive Officer | Jul 01 '26 | Sale | 20.03 | 47,775 | 956,933 | 2,877,118 | Jul 02 |
| Bodenstedt Matthias | Chief Financial Officer | Jun 22 '26 | Sale | 22.04 | 39,120 | 862,205 | 1,115,435 | Jun 23 |
| Bodenstedt Matthias | Chief Financial Officer | Jun 18 '26 | Sale | 19.60 | 2,794 | 54,762 | 1,154,555 | Jun 18 |
| Bodenstedt Matthias | Chief Financial Officer | Jun 17 '26 | Sale | 19.68 | 15,082 | 296,814 | 1,157,349 | Jun 18 |
| Reich Kristian | Chief Scientific Officer | Jun 17 '26 | Sale | 19.43 | 50,000 | 971,500 | 2,824,551 | Jun 17 |
| Reich Kristian | Chief Scientific Officer | Jun 16 '26 | Sale | 18.70 | 50,000 | 935,000 | 2,874,551 | Jun 17 |
| Reich Kristian | Chief Scientific Officer | Jun 15 '26 | Sale | 18.89 | 50,000 | 944,500 | 2,924,551 | Jun 17 |
| Bodenstedt Matthias | Chief Financial Officer | May 11 '26 | Sale | 20.02 | 13,653 | 273,333 | 1,172,431 | May 13 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.